HelpAcademyLoginJoin us as a Member

ALNYLAM PHARMACEUTICALS, INC.

Sign in to save ALNYLAM PHARMACEUTICALS, INC. to a watchlist Sign in to set an alert for ALNYLAM PHARMACEUTICALS, INC.
Tickers
ALNY
Headquarters
Not recorded
SEC CIK
0001178670
Website
Not recorded

Closing prices

Latest close, 174.00

Closing prices for ALNY249 stored closes for ALNY from 3 Nov 2025 to 29 Oct 2026. Lowest 174.00 on 29 Oct 2026, highest 473.29 on 3 Dec 2025, latest 174.00 on 29 Oct 2026.Close100.00200.00300.00400.00500.003 Nov 20251 May 202629 Oct 2026
249 stored closes, oldest first. End of day, not intraday.

Source: Massive Closing prices as of End-of-day prices, not live

Massive Basic, non-business use; display licence needed before launch (D-1). Marketstack is kept as the backup source.

Not investment advice. End-of-day closing prices, not live quotes.

Drugs

Drugs from ALNYLAM PHARMACEUTICALS, INC.
DrugIndicationsPhaseNext catalystCT-VCATrials
NucresiranNot yet reviewed: Listed from FDA or ClinicalTrials.gov records; an editor has not checked it yet Sign in to save Nucresiran to a watchlist Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; Transthyretin Amyloidosis With Cardiomyopathy; hATTR-PNPhase 3None scheduledNo published CT-VCA score2
ZilebesiranNot yet reviewed: Listed from FDA or ClinicalTrials.gov records; an editor has not checked it yet Sign in to save Zilebesiran to a watchlist High Cardiovascular Risk; High Risk Cardiovascular Disease; HypertensionPhase 3None scheduledNo published CT-VCA score1

FDA-approved applications

No Drugs@FDA application has a sponsor name that matches this company.

Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.

Catalysts

No catalysts yet. Editors add each date together with its source.

Deals

No approved deals involve this company yet.

Reported fundamentals (SEC XBRL)

Latest value of each metric as reported to the SEC
MetricReported valuePeriodFiling
Revenue1,458,086,000 USD 1 Jul 2026 to 30 Sep 2026 FY2026 Q310-Q for Revenue on sec.gov (opens in a new tab)Filed
Net income (loss)2,167,335,000 USD 1 Jul 2026 to 30 Sep 2026 FY2026 Q310-Q for Net income (loss) on sec.gov (opens in a new tab)Filed
Research and development expense408,538,000 USD 1 Jul 2026 to 30 Sep 2026 FY2026 Q310-Q for Research and development expense on sec.gov (opens in a new tab)Filed
Operating expenses1,112,288,000 USD 1 Jul 2026 to 30 Sep 2026 FY2026 Q310-Q for Operating expenses on sec.gov (opens in a new tab)Filed
Cash and cash equivalents1,754,340,000 USD At 30 Sep 2026 FY2026 Q310-Q for Cash and cash equivalents on sec.gov (opens in a new tab)Filed
Short-term investments and marketable securities1,832,915,000 USD At 30 Sep 2026 FY2026 Q310-Q for Short-term investments and marketable securities on sec.gov (opens in a new tab)Filed
Total liabilities4,390,820,000 USD At 30 Sep 2026 FY2026 Q310-Q for Total liabilities on sec.gov (opens in a new tab)Filed
Stockholders' equity3,603,852,000 USD At 30 Sep 2026 FY2026 Q310-Q for Stockholders' equity on sec.gov (opens in a new tab)Filed
Common shares outstanding (cover page)133,937,576 shares At 23 Oct 2026 FY2026 Q310-Q for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed

History

Revenue, newest period first
PeriodReported valueFiling
1 Jul 2026 to 30 Sep 2026 FY2026 Q31,458,086,000 USD10-Q filed 29 Oct 2026 on sec.gov (opens in a new tab)Filed
1 Apr 2026 to 30 Jun 2026 FY2026 Q21,290,948,000 USD10-Q filed 30 Jul 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2025 to 31 Dec 2025 FY20253,713,937,000 USD10-K filed 12 Feb 2026 on sec.gov (opens in a new tab)Filed
1 Jul 2025 to 30 Sep 2025 FY2026 Q31,249,026,000 USD10-Q filed 29 Oct 2026 on sec.gov (opens in a new tab)Filed
1 Apr 2025 to 30 Jun 2025 FY2026 Q2773,689,000 USD10-Q filed 30 Jul 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2024 to 31 Dec 2024 FY20252,248,243,000 USD10-K filed 12 Feb 2026 on sec.gov (opens in a new tab)Filed
1 Jul 2024 to 30 Sep 2024 FY2025 Q3500,919,000 USD10-Q filed 30 Oct 2025 on sec.gov (opens in a new tab)Filed
1 Apr 2024 to 30 Jun 2024 FY2025 Q2659,825,000 USD10-Q filed 31 Jul 2025 on sec.gov (opens in a new tab)Filed

The newest 12 periods of each metric are listed; older ones are on sec.gov.

Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.

Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-30 · read

SEC filings

SEC filings from ALNYLAM PHARMACEUTICALS, INC., newest first
FormFiledWhat it coversDocument
8-K Current report (8-K) View Current report (8-K) filed 29 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001178670-26-000074 (opens in a new tab)
10-Q Quarterly report (10-Q) View Quarterly report (10-Q) filed 29 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001178670-26-000076 (opens in a new tab)
4Event 2 Oct 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 6 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001178670-26-000068 (opens in a new tab)
4Event 19 Sep 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 22 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001178670-26-000065 (opens in a new tab)
10-QEvent 30 Jun 2026 Quarterly report (10-Q) View Quarterly report (10-Q) filed 30 Jul 2026 on sec.gov (opens in a new tab)Filing index for 0001178670-26-000062 (opens in a new tab)
8-K Current report (8-K)
  • Results of operations and financial condition (Item 2.02)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 30 Jul 2026 on sec.gov (opens in a new tab)Filing index for 0001178670-26-000060 (opens in a new tab)
4Event 1 Jun 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 3 Jun 2026 on sec.gov (opens in a new tab)Filing index for 0001178670-26-000048 (opens in a new tab)
4Event 1 Jun 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 3 Jun 2026 on sec.gov (opens in a new tab)Filing index for 0001178670-26-000047 (opens in a new tab)
8-KEvent 20 May 2026 Current report (8-K)
  • Departure or appointment of directors or officers (Item 5.02)
  • Shareholder vote results (Item 5.07)
View Current report (8-K) filed 27 May 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-038499 (opens in a new tab)
4Event 20 May 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 22 May 2026 on sec.gov (opens in a new tab)Filing index for 0001178670-26-000042 (opens in a new tab)

Source: SEC EDGAR. Each row links to the filing on sec.gov.

Related news

No recent headlines mention this company.

Insider transactions

All rows for ALNYLAM PHARMACEUTICALS, INC. on Insider Trades

Last 90 days of Form 4 filings, from 3 Aug 2026 (US Eastern dates).

Buys code P
None in this period
Sells code S
None in this period
Other all other codes
1 transaction: grants, exercises, tax withholding, gifts and similar

Last transaction:

Insider filings are public records and are not a recommendation. Source: SEC EDGAR.

Sources

Nothing on this page is investment advice.